National Stroke Foundation


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved June 1998

Specific Treatments:

respiratory syncytial virus (RSV)

General Information

Synagis has been approved for the prevention of serious lower respiratory tract disease in pediatric patients at high risk of RSV disease. Synagis is the first monoclonal antibody to be licensed for any infectious disease. It is injected intramuscularly in a doctor's office.